Subscribe To

Price Alert Latest News Economic Calendar News

PBLA / Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication

Data from phase 1b study using SBP-101 for patients with pancreatic cancer will be shown at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium on January 20- 22, 2022. Pancreatic cancer patients in cohort 2 given SBP-101 + chemotherapies achieved ORR of 71%; Cohort 4 patients achieved ORR of 48% but median overall survival has not yet been reached. Read More

Demo Live Account See Partner Details

Content Topics

Ping

Identity

Holding

Corp

Panbela

Biotech

Updated

Patent

Protection

Market

Target

Indication

Stock

PBLA

Posted: Jan 5 2022, 21:27

Author Name: Seeking Alpha

PBLA News

By GlobeNewsWire
October 24, 2023

Panbela to Host Third Quarter 2023 Earnings Conference Call on November 9, 2023

MINNEAPOLIS, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeuti

By GlobeNewsWire
August 28, 2023

Panbela to Present at H.C. Wainwright 25th Annual Global Investment Conference

MINNEAPOLIS, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical-stage biopharmaceutical company developing disru

By Seeking Alpha
August 10, 2023

Panbela Therapeutics, Inc. (PBLA) Q2 2023 Earnings Call Transcript

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants James Carbonara - Investor

By Zacks Investment Research
July 11, 2023

Panbela (PBLA) Up 11% on Update From Pancreatic Cancer Study

Panbela (PBLA) rises 11% on a positive recommendation from an independent board reviewing safety data from a late-stage study of ivospemin in the trea

By Seeking Alpha
May 7, 2023

Panbela Therapeutics, Inc. (PBLA) Q1 2023 Earnings Call Transcript

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q1 2023 Earnings Conference Call May 4, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR Jen

By GlobeNewsWire
April 24, 2023

Panbela to Host First Quarter 2023 Earnings Conference Call on May 4, 2023

MINNEAPOLIS, April 24, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutic

By Zacks Investment Research
April 13, 2023

Panbela (PBLA) Enrolls First Patient for Type 1 Diabetes Drug

Panbela (PBLA) surges as it enrolls the first patient in the mid-stage clinical study to evaluate CPP-1X-T (Eflornithine tablets) for treating recent-

By Seeking Alpha
March 16, 2023

Panbela Therapeutics, Inc. (PBLA) Q4 2022 Earnings Call Transcript

Panbela Therapeutics, Inc. (NASDAQ:PBLA ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants James Carbonara - Hayden IR

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.